Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC.
Integrated Ventures Inc. (OTCQB: INTV) has announced a strategic partnership through its subsidiary, MedWell USA, . The company has signed a Management Services Organization (MSO) agreement with an FDA-licensed pharmaceutical manufacturer, enabling MedWell USA to act as a Procurement Agent for Semaglutide, a leading weight management drug.
MedWell USA will target health providers, wellness clinics, and gyms across 23 states, expanding its presence in the health and wellness industry. The global market for Semaglutide is projected to reach $10.6 billion by 2028, with a CAGR of 14.5%.
The company plans to expand its offerings to include a broader range of pharmaceuticals and medical supplies, with potential for another MSO agreement for Tirzepatide, another GLP-1 based drug. Integrated Ventures Inc. aims to become a trusted partner in the healthcare and wellness industry through its subsidiary's B2B procurement services.
Integrated Ventures Inc. (OTCQB: INTV) ha annunciato una partnership strategica attraverso la sua sussidiaria, MedWell USA. L'azienda ha firmato un accordo di Management Services Organization (MSO) con un produttore farmaceutico autorizzato dalla FDA, che consente a MedWell USA di agire come Agente di Approvvigionamento per il Semaglutide, un farmaco leader nella gestione del peso.
MedWell USA si concentrerà su fornitori di salute, cliniche di benessere e palestre in 23 stati, espandendo la propria presenza nel settore della salute e del benessere. Si prevede che il mercato globale per il Semaglutide raggiunga $10,6 miliardi entro il 2028, con un CAGR del 14,5%.
L'azienda ha in programma di ampliare la propria offerta per includere un'ampia gamma di farmaci e forniture mediche, con il potenziale per un altro accordo MSO per il Tirzepatide, un altro farmaco basato sul GLP-1. Integrated Ventures Inc. punta a diventare un partner fidato nel settore sanitario e del benessere attraverso i servizi di approvvigionamento B2B della sua sussidiaria.
Integrated Ventures Inc. (OTCQB: INTV) ha anunciado una asociación estratégica a través de su subsidiaria, MedWell USA. La empresa ha firmado un acuerdo de Organización de Servicios de Gestión (MSO) con un fabricante farmacéutico autorizado por la FDA, lo que permite que MedWell USA actúe como Agente de Aprovisionamiento para Semaglutida, un medicamento líder en el manejo del peso.
MedWell USA se enfocará en proveedores de salud, clínicas de bienestar y gimnasios en 23 estados, ampliando su presencia en la industria de la salud y el bienestar. Se estima que el mercado global de Semaglutida alcanzará $10.6 mil millones para 2028, con una Tasa de Crecimiento Anual Compuesta (CAGR) del 14.5%.
La empresa planea expandir su oferta para incluir una gama más amplia de productos farmacéuticos y suministros médicos, con potencial para otro acuerdo MSO para Tirzepatida, otro medicamento basado en GLP-1. Integrated Ventures Inc. aspira a convertirse en un socio de confianza en la industria de la salud y el bienestar a través de los servicios de aprovisionamiento B2B de su subsidiaria.
인티그레이티드 벤처스 Inc. (OTCQB: INTV)는 자회사 메드웰 USA를 통해 전략적 파트너십을 발표했습니다. 이 회사는 FDA 승인을 받은 제약 제조업체와 관리 서비스 조직(MSO) 계약을 체결하여 메드웰 USA가 세마글루타이드 조달 대리인으로 활동할 수 있게 되었습니다. 세마글루타이드는 비만 관리의 주요 약물입니다.
메드웰 USA는 23개 주 전역의 건강 제공자, 웰니스 클리닉 및 체육관을 타겟으로 하여 건강 및 웰니스 산업에서의 존재를 확장할 것입니다. 세마글루타이드의 글로벌 시장은 2028년까지 106억 달러에 이를 것으로 예상되며, 연평균 성장률(CAGR)은 14.5%입니다.
회사는 티르제파타이드에 대한 또 다른 MSO 계약의 가능성을 포함하여 더 넓은 범위의 의약품 및 의료 용품을 제공하기 위해 제품 라인을 확장할 계획입니다. 인티그레이티드 벤처스 Inc.는 자회사의 B2B 조달 서비스를 통해 건강 및 웰니스 산업에서 신뢰받는 파트너가 되는 것을 목표로 하고 있습니다.
Integrated Ventures Inc. (OTCQB: INTV) a annoncé un partenariat stratégique par l'intermédiaire de sa filiale, MedWell USA. L'entreprise a signé un accord de Management Services Organization (MSO) avec un fabricant pharmaceutique agréé par la FDA, permettant à MedWell USA d'agir en tant que Gestionnaire d'approvisionnement pour le Semaglutide, un médicament phare pour la gestion du poids.
MedWell USA ciblera les prestataires de santé, les cliniques de bien-être et les salles de sport dans 23 États, élargissant ainsi sa présence dans l'industrie de la santé et du bien-être. Le marché mondial du Semaglutide devrait atteindre 10,6 milliards de dollars d'ici 2028, avec un Taux de Croissance Annuel Composé (CAGR) de 14,5%.
L'entreprise envisage d'élargir son offre pour inclure un éventail plus large de produits pharmaceutiques et de fournitures médicales, avec un potentiel pour un autre accord MSO pour le Tirzepatide, un autre médicament basé sur le GLP-1. Integrated Ventures Inc. vise à devenir un partenaire de confiance dans l'industrie de la santé et du bien-être grâce aux services d'approvisionnement B2B de sa filiale.
Integrated Ventures Inc. (OTCQB: INTV) hat eine strategische Partnerschaft über seine Tochtergesellschaft MedWell USA angekündigt. Das Unternehmen hat einen Vertrag über eine Management Services Organization (MSO) mit einem von der FDA lizenzierten Pharmahersteller unterzeichnet, der es MedWell USA ermöglicht, als Beschaffungsagent für Semaglutid, ein führendes Mittel zur Gewichtsregulierung, zu fungieren.
MedWell USA wird Gesundheitsdienstleister, Wellnesskliniken und Fitnessstudios in 23 Bundesstaaten anvisieren und seine Präsenz in der Gesundheits- und Wellnessindustrie ausbauen. Der globale Markt für Semaglutid wird voraussichtlich bis 2028 10,6 Milliarden USD erreichen, mit einer jährlichen Wachstumsrate (CAGR) von 14,5%.
Das Unternehmen plant, sein Angebot zu erweitern, um eine breitere Palette von Arzneimitteln und medizinischen Produkten einzubeziehen, mit dem Potenzial für einen weiteren MSO-Vertrag für Tirzepatid, ein weiteres Medikament auf GLP-1-Basis. Integrated Ventures Inc. will durch die B2B-Beschaffungsdienste seiner Tochtergesellschaft ein vertrauenswürdiger Partner in der Gesundheits- und Wellnessbranche werden.
- Strategic partnership enabling MedWell USA to act as a Procurement Agent for Semaglutide
- Expansion into 23 states, targeting health providers, wellness clinics, and gyms
- Global Semaglutide market projected to reach $10.6 billion by 2028, with 14.5% CAGR
- Potential for additional MSO agreement for Tirzepatide procurement
- Diversification of business operations into digital currency mining, healthcare procurement, telemedicine, and facilities management
- None.
This agreement enables MedWell
Semaglutide, a GLP-1 receptor agonist, has gained significant traction as an effective treatment for weight loss and management. The consumer market for Semaglutide is rapidly expanding, with the global market projected to reach
Through this MSO agreement, MedWell
"We are excited to announce this pivotal MSO agreement that empowers MedWell
"The Semaglutide market presents a significant opportunity, and we are committed to leveraging this agreement to provide top-tier pharmaceutical products to health and wellness clinics. We are anticipating signing of another MSO, which will enable MedWell
MedWell
Integrated Ventures, Inc.: The Company, located in
The Company's current operations consist of:
(1) Digital currency mining and hosting.
(2) MedWell
(3) MedWell Direct, LLC – Operator of D2B/B2C telemedicine platforms that connect consumers with licensed healthcare providers and provides weight loss management services, driven by GLP-1 products.
(4) MedWell Facilities, LLC - Facilities management company is dedicated to the health and wellness industry. This subsidiary is focused on developing real estate opportunities, designed to attract health and wellness tenants.
Safe Harbor Statement: The information posted in this release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of1995. You can identify these statements by use of the words "may," "will," "should," "plans," "explores," "expects," "anticipates," "continue," "estimate," "project," "intend," and similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, and various other factors beyond the company's control.
Contact Details: (215) 613-9898 sr@integratedventures.io
View original content:https://www.prnewswire.com/news-releases/integrated-ventures-inc-announces-strategic-partnership-for-glp-1-semaglutide-procurement-through-medwell-usa-llc-302257074.html
SOURCE Integrated Ventures Inc.
FAQ
What is the new strategic partnership announced by Integrated Ventures Inc. (INTVD)?
How many states will MedWell USA, target for its Semaglutide procurement services?
What is the projected market size for Semaglutide by 2028, according to Integrated Ventures Inc. (INTVD)?
What other pharmaceutical product does Integrated Ventures Inc. (INTVD) plan to include in its procurement services?
